Immune alterations and emerging immunotherapeutic approaches in lung cancer.
about
Immunotherapy for stage I-III non-small cell lung cancer treated with surgery or radiotherapy with curative intentNew modalities of cancer treatment for NSCLC: focus on immunotherapyThe role of the immune system in non-small cell lung carcinoma and potential for therapeutic interventionAntibody Therapies in Cancer.PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation.Effects of transcutaneous acupoint electrical stimulation on the imbalance of Th1, Th2, Th17 and Treg cells following thoracotomy of patients with lung cancer.Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapies.Elevated regulatory T cells, surface and intracellular CTLA-4 expression and interleukin-17 in the lung cancer microenvironment in humans.Immune alterations and immunotherapy prospects in head and neck cancer.New treatment options for lung adenocarcinoma--in view of molecular background.Updates on immunotherapy in non-small cell lung cancer.PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy.Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer.Emerging drugs targeting PD-1 and PD-L1: reality or hope?Immunotherapy in lung cancer.Mechanisms of immune response regulation in lung cancer.Targeting the immune system to treat lung cancer: rationale and clinical experience.Recent developments in the use of immunotherapy in non-small cell lung cancer.MUC1 aptamer-based near-infrared fluorescence probes for tumor imaging.Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.Pulmonary Sarcoidosis Activation following Neoadjuvant Pembrolizumab plus Chemotherapy Combination Therapy in a Patient with Non-Small Cell Lung Cancer: A Case Report.Effects of talactoferrin alpha on lung adenoma prevention in A/J mice June 2, 2016.Immunosuppressive Role of Myeloid-Derived Suppressor Cells and Therapeutic Targeting in Lung Cancer.
P2860
Q24194081-51171FBC-9934-4BE8-ACFD-A6B355CB79D3Q26829161-11A54573-6FE5-4DF6-B89F-44B2B87E60CBQ27024781-D2F415B3-6D94-4ED7-A332-96DF03EB65B3Q31104000-D2134AFE-2875-4B21-8345-9C0EC650EBB2Q34996125-39E67492-7A7F-4AD1-8E93-3D9FEFCFE9FDQ36524648-6CE0113F-4B8F-4F53-9891-2D98D647925FQ36946100-9ACE4DF3-23EE-4B7C-9715-F5B3739ED773Q37614743-5C674D67-180C-4EBA-91C0-CCD25467B3B7Q38116067-83F9B2D1-90B8-4889-B525-E0C0D38FD35DQ38168761-2C7257A9-A642-4092-8414-FE1CFFDF9258Q38186794-2CA9FE7C-8842-429B-9645-F08224A4C5ACQ38222469-65583251-604C-49F8-AE50-B3099036F79BQ38245669-9CA6D8FD-1377-4887-8A58-8EC4C80E5D59Q38254083-7ECE4C19-BB83-4DC3-AB6B-EB3834BE9146Q38390093-D753C10C-A1E5-4942-AE6B-E1A544731226Q38390097-F68A5A72-DCDE-4A7F-8B57-7B5CA1BC2CD0Q38397629-87FBBE67-73F1-40AA-84C7-EA9007D97026Q38826419-73FA73AB-43BC-4C24-845A-E5584B0CBFD8Q38977046-9243BD86-2416-4CE4-BAAB-581CA25DE6CAQ47299048-A7A4975E-8B34-4E91-AA03-60B0D2BDE5F7Q52668433-101FC099-BCC1-4A23-A336-5825C443E478Q52720148-AB01733A-CB2C-4BAF-AEED-72A6F8280368Q54918600-A588D1CF-D922-4175-AB5B-FEE2A8FBAEF5
P2860
Immune alterations and emerging immunotherapeutic approaches in lung cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Immune alterations and emerging immunotherapeutic approaches in lung cancer.
@en
type
label
Immune alterations and emerging immunotherapeutic approaches in lung cancer.
@en
prefLabel
Immune alterations and emerging immunotherapeutic approaches in lung cancer.
@en
P2093
P2860
P1476
Immune alterations and emerging immunotherapeutic approaches in lung cancer.
@en
P2093
Constantin A Dasanu
Nausheen Ahmed
Nishant Sethi
P2860
P304
P356
10.1517/14712598.2012.685715
P407
P577
2012-05-05T00:00:00Z